Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

SAFC Gets License To Oligo Process

May 28, 2007 | A version of this story appeared in Volume 85, Issue 22

Sigma-Aldrich's SAFC custom manufacturing business has received a license to Beckman Coulter's fast deprotection chemistry. According to SAFC, the deal covers Beckman's acetyl-protected cytidine DNA and 2′-O-methyl phosphoramidites for the synthesis of oligonucleotides. The company says it will use the technology to produce reagents at its facility in Hamburg, Germany. SAFC notes that oligo-based therapies are the focus of more than 120 preclinical studies or clinical trials around the world.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.